DoD tests AI models that make it easy to switch from vendors like Palantir
Investing.com - RBC Capital has raised its price target on Boston Scientific (NYSE:BSX) to $125.00 from $120.00 while maintaining an Outperform rating on the medical device maker’s stock. The new target reflects growing analyst optimism, with InvestingPro data showing 16 analysts recently revising their earnings estimates upward, and the stock currently trading near its 52-week high of $108.94.
The price target increase follows Boston Scientific’s second quarter 2025 results, which showed 17% year-over-year organic revenue growth, outperforming end-markets by 890 basis points, and a 23% year-over-year increase in earnings per share.
Boston Scientific has raised its 2025 revenue growth guidance by 150 basis points to 14-15% year-over-year and increased its operating margin guidance by 75-100 basis points versus the previous 50-75 basis points, while absorbing $200 million in tariffs and the exit from its TAVR business.
The strong quarterly performance drove Boston Scientific’s stock up 3.5% on the day results were announced, despite what RBC Capital described as "the high bar" of expectations.
RBC Capital views Boston Scientific as among the highest-performing large-cap medical technology companies, with potential for continued earnings beats and guidance raises, driven by execution, innovation, and strong end-markets.
In other recent news, Boston Scientific has reported robust second-quarter financial results, with sales reaching $5.06 billion, marking a 17.4% organic growth. This performance exceeded analyst expectations of $4.9 billion. The company’s electrophysiology division, particularly the Pulse Field Ablation (PFA) technology, demonstrated significant momentum, with U.S. growth hitting 117% year-over-year. Analysts from several firms have responded positively to these results. Bernstein raised its price target for Boston Scientific to $130, highlighting the company’s strong quarterly performance. Mizuho (NYSE:MFG) increased its price target to $140, citing the strong performance of the FARAPULSE and WATCHMAN product lines. UBS also raised its target to $135, noting the company’s strong product cycle and sales performance. Meanwhile, Wells Fargo (NYSE:WFC) adjusted its target to $124, emphasizing the growth in PFA technology, and BofA Securities set a new target of $120, following an analysis of the company’s financial outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.